Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
RR 0.72 [0.47, 1.11]
3 studies · 333 participants
Very low
RR 0.68 [0.48, 0.97]
1 study · 238 participants
Low
RR 0.75 [0.6, 0.94]
5 studies · 723 participants
Moderate
Length of hospital stay · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Mortality before hospital discharge · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes all‐cause mortality prior to hospital discharge compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (at end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review